 |
|
The Quality of Antipsychotic Drug Prescribing in Nursing Homes
Becky A. Briesacher, PhD;
M. Rhona Limcangco, PhD;
Linda Simoni-Wastila, PhD;
Jalpa A. Doshi, PhD;
Suzi R. Levens, MD;
Dennis G. Shea, PhD;
Bruce Stuart, PhD
Arch Intern Med. 2005;165:1280-1285.
Background The prescribing of antipsychotic drugs has been increasing in nursing homes (NHs) since the availability of second-generation antipsychotic agents, also known as the atypicals, but there is little information on the appropriateness of such prescribing.
Methods A retrospective analysis using the nationally representative data set of the Medicare Current Beneficiary Survey merged to Minimum Data Sets assessments, medication administration records, and Medicare claims. We identified a sample of 2.5 million Medicare beneficiaries in NHs during 2000-2001 (unweighted n = 1096) to assess prevalence of antipsychotic use, rates of adherence to NH prescribing guidelines, and changes in behavioral symptoms.
Results Approximately 693 000 (unweighted n = 302), or 27.6%, of all Medicare beneficiaries in NHs received at least 1 prescription for antipsychotics during the study period: 20.3% received atypicals only; 3.7%, conventionals only; and 3.6%, both atypicals and conventionals. Less than half (41.8%) of treated residents received antipsychotic therapy in accordance with NH prescribing guidelines. One (23.4%) in 4 patients had no appropriate indication, 17.2% had daily doses exceeding recommended levels, and 17.6% had both inappropriate indications and high dosing. Patients receiving antipsychotic therapy within guidelines were no more likely to achieve stability or improvement in behavioral symptoms than were those taking antipsychotics outside the guidelines.
Conclusions This study detected the highest level of antipsychotic use in NHs in over a decade. Most atypicals were prescribed outside the prescribing guidelines and for doses and indications without strong clinical evidence. Failure to detect positive relationships between behavioral symptoms and antipsychotic therapy raises questions about the appropriateness of prescribing.
Author Affiliations: University of Massachusetts Medical School, Worcester (Dr Briesacher); School of Pharmacy, University of Maryland, Baltimore (Drs Limcangco, Simoni-Wastila, and Stuart); General Internal Medicine, University of Pennsylvania, Philadelphia (Dr Doshi); Leonard Davis Institute of Health Economics, Philadelphia (Dr Doshi); and The Pennsylvania State University, University Park (Drs Levens and Shea).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck et al.
Arch Gen Psychiatry 2007;64:1259-1268.
ABSTRACT
| FULL TEXT
Antipsychotic drugs and the acute respiratory distress syndrome
Wilson and Ridley
Br J Anaesth 2007;99:301-302.
FULL TEXT
Variation in Nursing Home Antipsychotic Prescribing Rates
Rochon et al.
Arch Intern Med 2007;167:676-683.
ABSTRACT
| FULL TEXT
Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients
Schneeweiss et al.
CMAJ 2007;176:627-632.
ABSTRACT
| FULL TEXT
Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review.
Ayalon et al.
Arch Intern Med 2006;166:2182-2188.
ABSTRACT
| FULL TEXT
Use of antipsychotics among nonagenarian residents in long-term institutional care in Finland
Alanen et al.
Age Ageing 2006;35:508-513.
ABSTRACT
| FULL TEXT
Implications of part d for mentally ill dual eligibles: a challenge for medicare.
Morden and Garrison
Health Aff (Millwood) 2006;25:491-500.
ABSTRACT
| FULL TEXT
Risk of death in elderly users of conventional vs. atypical antipsychotic medications.
Wang et al.
NEJM 2005;353:2335-2341.
ABSTRACT
| FULL TEXT
|
